10-K: Merit Medical Reports Record Revenue in 2023, Driven by Strong US Demand and International Growth

Merit Medical Systems, Inc., a leading manufacturer of medical devices, announced record sales of $1.257 billion for the year ended December 31, 2023, marking a 9.2% increase from 2022, fueled by robust demand in the U.S. and favorable international sales trends.

Summary

• Merit Medical Systems, Inc. reported sales of $1.257 billion for the year ended December 31, 2023, a 9.2% increase compared to 2022 sales of $1.151 billion.
• The revenue growth in 2023 was primarily driven by stronger-than-anticipated demand in the U.S. and favorable international sales trends, particularly in the EMEA and Rest of World regions.
• Gross profit as a percentage of sales was 46.4% in 2023, up from 45.1% in 2022.
• Net income for 2023 was $94.4 million, or $1.62 per share, compared to $74.5 million, or $1.29 per share, in 2022.
• In June 2023, Merit completed the acquisition of a portfolio of dialysis catheter products and the BioSentry Biopsy Tract Sealant System from AngioDynamics, as well as the Surfacer Inside-Out Access Catheter System from Bluegrass.
• The company completed its Foundations for Growth Program in 2023, meeting or exceeding financial targets, and introduced the Continued Growth Initiatives Program with new multi-year financial targets through 2026.
• In December 2023, Merit closed an offering of $747.5 million in 3.00% Convertible Senior Notes due 2029, with proceeds intended for general corporate purposes, including debt repayment, sales and marketing, research and development, and potential acquisitions.

Sentiment

Score: 8

Explanation: The document reflects a strong financial performance with record sales and increased net income. The company's strategic acquisitions, new growth initiatives, and successful capital raise contribute to a positive outlook. However, challenges in the Chinese market and ongoing regulatory and operational risks temper the sentiment slightly.

Positives

• Record sales performance in 2023, exceeding $1.257 billion.
• Strong growth in both U.S. and international markets.
• Successful completion of strategic acquisitions, expanding product portfolio.
• Improvement in gross profit margin.
• Significant increase in net income.
• Introduction of a new growth initiative program.
• Successful issuance of convertible notes, providing financial flexibility.

Negatives

• Experienced decreased sales prices and volumes in China due to the Volume-Based Procurement (VBP) policy.
• Incurred significant expenses related to acquisitions and integration activities.
• Faced challenges related to supply chain disruptions and increased costs for raw materials, labor, and transportation.
• Operating under a Corporate Integrity Agreement (CIA) with the Office of Inspector General (OIG), which imposes compliance and reporting obligations.

Risks

• Termination or interruption of supply relationships and increases in the cost of component parts, finished products, third-party services, and raw materials.
• Changes in economic and geopolitical conditions, domestic and foreign trade policies, monetary policies, and other factors beyond the company's control.
• Regulations and trade policies implemented by foreign governments, particularly the VBP policy in China.
• The FDA regulatory clearance process is expensive, time-consuming, and uncertain.
• Potential product liability claims and warranty claims.
• Dependence on key personnel, including the anticipated retirement of the CEO.
• Compliance with the Corporate Integrity Agreement (CIA) and potential penalties for non-compliance.
• Potential impact of environmental, health, and safety laws and regulations, including those related to PFAS and EtO.
• Cybersecurity risks and reliance on information technology systems.
• Fluctuations in foreign currency exchange rates.

Future Outlook

Merit Medical has introduced the Continued Growth Initiatives Program with new multi-year financial targets for the three-year period ending December 31, 2026. The company anticipates spending approximately $50 to $60 million on property and equipment in 2024. They believe existing cash balances, future cash flows from operations, and borrowings under long-term debt agreements will be adequate to fund operations for the next twelve months and the foreseeable future.

Management Comments

• We strive to be the most customer-focused company in healthcare.
• Each day we are determined to make a difference by understanding our customers needs and innovating and delivering a diverse range of products that improve the lives of people and communities throughout the world.
• We believe that long-term value is created for our customers, employees, shareholders, and communities when we focus outward and are determined to deliver an exceptional customer experience.

Industry Context

The medical device industry is highly competitive and subject to rapid technological advancements. Consolidation in the healthcare industry and the influence of group purchasing organizations are putting pressure on prices. Regulatory scrutiny and compliance costs are increasing globally, particularly with the implementation of the EU's MDR.

Comparison to Industry Standards

• Compared to Teleflex Incorporated, Merit Medical has a broader line of ancillary products and stronger manufacturing integration.
• Compared to Cook Medical, Merit Medical has shown a stronger cadence of new product introductions and product line extensions.
• Compared to Medtronic, Merit Medical has a smaller market presence but competes effectively in specific product lines like digital inflation technology.
• Compared to Boston Scientific, Merit Medical has a more focused approach in interventional cardiology and peripheral intervention.
• Compared to Becton, Dickinson and Company (BD), Merit Medical has a more comprehensive portfolio in certain areas like radar localization and waste-disposal systems.
• Compared to Abbott Laboratories, Merit Medical has a niche position in the cardiac intervention market.
• Compared to Terumo Corporation, Merit Medical has a growing presence in the radial access market.
• Compared to Edwards Lifesciences Corporation, Merit Medical competes in different segments of the cardiac intervention market.
• Compared to Stryker Corporation, Merit Medical has a smaller presence in the spine market but offers specialized products like the STAR Tumor Ablation System.
• Compared to Johnson & Johnson, Merit Medical has a niche position in the spine market with products for vertebral augmentation and radiofrequency ablation.
• Compared to Hologic, Inc., Merit Medical competes in the breast cancer localization market with its SCOUT Radar Localization System.
• Compared to Endomagnetics Ltd., Merit Medical offers a nonradioactive, wire-free tumor localization system.
• Compared to Argon Medical Devices, Inc., Merit Medical has a broader portfolio of oncology products.
• Compared to Getinge AB, Merit Medical has a growing presence in the endoscopy market.
• Compared to Olympus Corporation, Merit Medical offers a range of gastroenterology and pulmonary products in the endoscopy market.

Management Changes

Legal Proceedings

• On June 3, 2021, a complaint was filed derivatively on behalf of Merit, against Merit (as a nominal defendant), our Chief Executive Officer, our Chief Financial Officer, our former President of EMEA and certain of our directors in the United States District Court for the District of Utah. The parties negotiated an agreement to settle the dispute, which was approved by the court on February 16, 2023.
• Merit has received requests from the Division of Enforcement of the U.S. Securities and Exchange Commission (SEC) seeking the voluntary production of information relating to the business activities of Merits subsidiary in China, including interactions with hospitals and health care officials in China.

Related Party Transactions

• As a former shareholder of Cianna Medical, a former Merit director was eligible for payments for the achievement of sales milestones specified in our merger agreement with Cianna Medical completed in 2018. During 2023, we made the final contingent payment to Cianna Medical Shareholders, including $0.9 million paid to the former Merit director who is a former Cianna Medical shareholder.

Stakeholder Impact

• Shareholders: Potential positive impact due to record sales, increased net income, and new growth initiatives. However, risks related to regulatory challenges, market competition, and the CEO's anticipated retirement could impact shareholder value.
• Employees: Continued focus on talent development, diversity, equity, and inclusion, and employee engagement. Potential impact from the CEO's planned retirement and any resulting organizational changes.
• Customers: Continued emphasis on providing innovative medical devices and solutions. Potential impact from changes in product availability due to regulatory requirements or supply chain disruptions.
• Suppliers: Potential impact from changes in demand for raw materials and components, as well as increased scrutiny of labor standards in the supply chain.
• Creditors: The company's strong financial performance and successful capital raise may have a positive impact on its ability to service debt. However, increased debt levels and potential future acquisitions could impact creditors.

Next Steps

• Continue to implement the Continued Growth Initiatives Program.
• Focus on sales and marketing activities, medical affairs, and educational efforts.
• Invest in research and development and clinical studies.
• Monitor and adapt to the evolving regulatory landscape, particularly in China and the EU.
• Evaluate potential acquisitions and strategic transactions.
• Manage supply chain risks and cost pressures.
• Address any issues arising from the SEC inquiry related to activities in China.

Key Dates

Keywords

medical devices, interventional procedures, diagnostic procedures, cardiology, radiology, oncology, critical care, endoscopy, peripheral intervention, cardiac intervention, custom procedural solutions, OEM, volume-based procurement, VBP, healthcare, acquisition, divestiture, research and development, international sales, China, EMEA, supply chain, FDA, regulation, compliance, corporate integrity agreement, CIA, sustainability, ESG